Rani Therapeutics Holdings

Company snapshot

Rani Therapeutics is a clinical-stage biotech company that has developed a platform technology to enable oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs, the vast majority of which must be injected. We have developed the RaniPill™ technology to replace subcutaneous or IV injections of biologics with an oral pill. The RaniPill™ capsule is designe

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 148 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Rani Therapeutics Holdings. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Rani Therapeutics Holdings.

1. Jun 8, 2026 Clinical update

   GRT-1C101 — Phase 1

2. Jun 8, 2026 Clinical update

   GRT-1C102 — Phase 1

3. Jun 8, 2026 Clinical update

   Berubicin hydrochloride — Phase 2

4. Jun 5, 2026 Clinical update

   RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity — Phase 1

5. Jun 5, 2026 Clinical update

   RaniPill capsule containing octreotide — Phase 1

View all clinical trial activity →

• What is Rani Therapeutics Holdings?

  Rani Therapeutics is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker RANI. Primary therapeutic focus areas include Ulcerative colitis, central nervous system (CNS) lymphomas, Obesity. NovaPharmaNews links 7 clinical program(s), 0 drug profile(

• Is Rani Therapeutics Holdings publicly traded?

  Yes. Rani Therapeutics Holdings is listed with ticker RANI on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Rani Therapeutics Holdings develop or market?

  We link 12 drug profile(s) where Rani Therapeutics Holdings is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/rani-therapeutics-holdings#company-drugs.

• What are the latest developments for Rani Therapeutics Holdings?

  In the last 12 months our linked public records show 7 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Rani Therapeutics Holdings focus on?

  Rani Therapeutics Holdings focuses on Ulcerative colitis, central nervous system (CNS) lymphomas, Obesity based on our analysis of their pipeline programs and drug development activities.